OnKure Therapeutics Financials - Benzinga

OnKure Therapeutics Inc

OKURNASDAQ

Trade with Public

Trade with Public

$3.58

0.020.56%

At close: Sep 4, 5:00 PM EST

$3.58

N/A

After Hours: Sep 4, 4:01 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

OnKure Therapeutics Financials

OnKure Therapeutics (OKUR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
CORRECTION: OnKure Therapeutics Q2 EPS $(0.31) Beats $(0.54) Estimate

OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 41.51 percent. This is a 72.81 percent increase over losses of $(1.14) per share

Benzinga Newsdesk

PRO
OnKure Therapeutics Q1 EPS $(1.11) Misses $(0.64) Estimate

OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.64) by 73.44 percent. This is a 6.72 percent increase over losses of $(1.19) per share

Benzinga Newsdesk

PRO
OnKure Therapeutics Q4 EPS $(0.99) Misses $(0.75) Estimate

OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.75) by 32 percent. This is a 27.74 percent increase over losses of $(1.37) per share

Benzinga Newsdesk

PRO
OnKure Therapeutics Q3 EPS $(1.09) Beats $(1.22) Estimate

Benzinga Newsdesk

PRO
OnKure Therapeutics Q2 EPS $(1.14) Beats $(1.26) Estimate

OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.26) by 9.88 percent. This is a 97.46 percent increase over losses of $(44.82) per share

Benzinga Newsdesk

PRO
OnKure Therapeutics Q1 EPS $(1.19) Beats $(1.46) Estimate

OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(1.46) by 18.49 percent.

Benzinga Newsdesk